In this issue:
Hypophosphataemia with ferric derisomaltose vs. ferric carboxymaltose in iron-deficiency anaemia
Tenalisib in relapsed/refractory haematological malignancies
Infection risk with ibrutinib in patients with B-cell malignancies
Long-term survival in MDS treated with 5-azaciditine
Thalidomide + dexamethasone-based regimens for relapsed/refractory MM after chemotherapy
Ropeginterferon alfa-2b vs. standard therapy for polycythaemia vera
Clinical features and outcomes of SDS with MDS or AML
Long-term siltuximab safety in idiopathic multicentric Castleman disease
Acalabrutinib monotherapy for Waldenström’s macroglobulinemia
CD19/22 CAR T-cell therapy in refractory/relapsed B-cell malignancies
Please login below to download this issue (PDF)